Field Trip Toronto
of Canadian employees are currently experiencing a mental health problem.
the average number of workdays missed annually by people with depression.
of disability costs are attributable to mental illness.
Employees with treatment-resistant depression are 14x more likely to make a long-term disability claim
Depression relapse rates increase with every antidepressant switch.
A new solution
Ketamine is a dissociative anaesthetic that was first approved by the FDA 50 years ago. Used in sub-anaesthetic doses, it has demonstrated strong efficacy and safety in the treatment of psychiatric and substance use disorders.
Acting as an NMDA receptor antagonist, ketamine induces neuroplasticity and reduces the activity of the Default Mode Network, which is neurologically analogous to the “ego” and, when overactive, can keep the mind stuck in old thinking patterns and harmful behaviours. Ketamine can be safely administered alongside conventional antidepressant medications (i.e. SSRIs, SNRIs).Our Process
WHAT WE OFFER
Free consultation sessions
Tailored treatment programs
Beautiful clinic spaces
Virtual therapy options
Mental wellness tools and education
Custom employee landing pages
Care tailored to employee needs
Improved employee well-being
Improved employee productivity
Reduced disability claims
Reduced healthcare costs
Dr. Tom Insel · Former Director, nimh
our medical professionals
Dr. Michael Verbora, M.D., MBA, studied at the Schulich School of Medicine at Western University before working as a leading physician in several Ontario clinics.
Dr. Joseph A. De Leo, Ph.D., C.Psych. is a licensed Clinical and Rehabilitation Psychologist with the College of Psychologists of Ontario, with a PhD in Clinical Psychology from the University at Albany.
Dr. Pinhas is Assistant Professor at the Department of Psychiatry at the University of Toronto, which she has been affiliated with for over 20 years.
Mr. Weinand is the former President, CEO and Chairman of the Board of Bayer Pharmaceuticals, AG and has 30 years of experience in senior executive roles with a number of pharmaceutical companies, including Sanofi, Otzuka and Pfizer.
Ms. Boudreau joins the Company’s Board of Directors after serving as COO for the Bill & Melinda Gates Medical Research Institute. Prior to that role, Ms. Boudreau served as CFO for biotech companies Proteostasis Therapeutics and FORMA Therapeutics.
Currently CEO of Limelight Bio and Chief Scientific Officer of Apple Tree Partners, Dr. Ehlers was previously Executive Vice President and Head of Research & Development at Biogen, one of the world’s oldest and largest biopharmaceutical companies.
Please fill out the form and we will contact you as soon as possible.
Where are we?
30 Duncan Street, Suite 400, Toronto, ON, M5V 2C3View in google maps
Call: 1-833-222-0084 | Fax: 1-855-933-1211